Clinical trial
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
NCT00442533 is registered in ClinicalTrials.gov with Radio Isotope Therapy of America as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
- Lead sponsor
- Radio Isotope Therapy of America
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- August 31, 2005
- Completion date
- December 28, 2015
- Enrollment
- 200 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.